GL Pharm Tech Corp banner
G

GL Pharm Tech Corp
KOSDAQ:204840

Watchlist Manager
GL Pharm Tech Corp
KOSDAQ:204840
Watchlist
Price: 1 056 KRW -2.58% Market Closed
Market Cap: ₩81.9B

Multiples-Based Value

The Multiples-Based Value for GL Pharm Tech Corp (204840) under the Base Case is hidden KRW. Compared with the current market price of 1 056 KRW, the stock appears hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GL Pharm Tech Corp Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
GL Pharm Tech Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
GL Pharm Tech Corp
KOSDAQ:204840
81.5B KRW 2.4 265.3 53.1 152.4
US
Eli Lilly and Co
NYSE:LLY
837.7B USD 12.9 40.6 27.4 29.3
US
Johnson & Johnson
NYSE:JNJ
583.9B USD 6.2 21.8 15.1 18.6
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.4 11.5 13
UK
AstraZeneca PLC
LSE:AZN
228B GBP 5.2 30 16.6 23.4
US
Merck & Co Inc
NYSE:MRK
292.3B USD 4.5 16 9.9 12.1
CH
Novartis AG
SIX:NOVN
229.9B CHF 5.3 21.5 13.3 17.1
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
US
Pfizer Inc
NYSE:PFE
157.9B USD 2.5 20.3 7.8 10.4
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.3 9.9 7.4 8.7
US
Bristol-Myers Squibb Co
NYSE:BMY
120.2B USD 2.5 17.1 7.2 8.9
P/E Multiple
Earnings Growth PEG
KR
G
GL Pharm Tech Corp
KOSDAQ:204840
Average P/E: 46.2
265.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.6
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.8
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.4
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
30
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16
14%
1.1
CH
Novartis AG
SIX:NOVN
21.5
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
20.3
22%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.1
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
G
GL Pharm Tech Corp
KOSDAQ:204840
Average EV/EBITDA: 49.5
53.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
27.4
22%
1.2
US
Johnson & Johnson
NYSE:JNJ
15.1
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.6
13%
1.3
US
Merck & Co Inc
NYSE:MRK
9.9
3%
3.3
CH
Novartis AG
SIX:NOVN
13.3
5%
2.7
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
-9%
N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.4
1%
7.4
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
G
GL Pharm Tech Corp
KOSDAQ:204840
Average EV/EBIT: 112.3
152.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.3
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
18.6
6%
3.1
CH
Roche Holding AG
SIX:ROG
13
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
23.4
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
CH
Novartis AG
SIX:NOVN
17.1
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
-4%
N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.7
2%
4.3
US
Bristol-Myers Squibb Co
NYSE:BMY
8.9
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett